Agendia, Inc., an Irvine, CA- and Amsterdam, The Netherlands-based precision oncology company, completed a $35m financing round.
Investment funds managed by Athyrium Capital Management provided the financing. Athyrium will be represented on the Agendia Board with the appointment of a Non-Executive Director.
The company intends to use the proceeds to accelerate commercial expansion in the U.S. and international markets, including increasing adoption of its sequencing-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit, invest in its Big Data programs which include full-genome profiling trials FLEX (U.S.) and PRECiSE (Netherlands), as well as establish new collaborative research programs with academic institutions to further the development of its precision oncology pipeline.
Led by Mark R. Straley, Chief Executive Officer, Agendia is a precision oncology company that develops and markets genomic diagnostic products, which help support physicians with their complex treatment decisions.
Its offerings include the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test, and the BluePrint® Molecular Subtyping Test, both on microarray technology, and the new MammaPrint BluePrint Recurrence and Molecular Subtyping test, on NGS technology.
In addition, the company has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostic tests in the area of oncology.